Identification of anesthetic.induced expression changes using DNA microarray

Molecular Medicine Reports

Volumn 11, Issue 1, 2015, Pages 589-596

  Yang, Zaiqi ^a,b   Zhang, Mengyuan ^a   Wang, Gongming ^a   Wei, Pihong ^b   Gao, Shenqiang ^b  

^a SHANDONG UNIVERSITY   (China)

^b Taian Central Hospital   (China)

Author keywords

Coronary Artery Bypass Grafting; Differentially Expressed Genes; Propofol; Sevoflurane

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 3; CALCINEURIN; CARBOXYPEPTIDASE; CARBOXYPEPTIDASE X; COLONY STIMULATING FACTOR 1; DUAL SPECIFICITY PHOSPHATASE; DUAL SPECIFICITY PHOSPHATASE 4; FIBROBLAST GROWTH FACTOR RECEPTOR 2; FIBRONECTIN; FIBRONECTIN LEUCINE RICH TRANSMEMBRANE PROTEIN 3; INSULIN RECEPTOR SUBSTRATE 1; INTERLEUKIN 15 RECEPTOR ALPHA; INTERLEUKIN 17 RECEPTOR; INTERLEUKIN 6 RECEPTOR; LEUCINE RICH REPEAT CONTAINING 32; MEMBRANE PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 3; PROPOFOL; PROTEIN SERINE THREONINE KINASE; PROTEIN SH2; PROTEIN TYROSINE PHOSPHATASE 1B; REGULATOR OF CALCINEURIN 1; SEVOFLURANE; STAT3 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 1; TRANSCRIPTION FACTOR FOSB; TRANSCRIPTION FACTOR JUNB; TRANSCRIPTION FACTOR JUND; TUMOR NECROSIS FACTOR ALPHA INDUCED PROTEIN 3; UNCLASSIFIED DRUG; ANESTHETIC AGENT; ETHER DERIVATIVE; INHALATION ANESTHETIC AGENT; INTRAVENOUS ANESTHETIC AGENT;

ARTICLE; CLINICAL ARTICLE; DNA MICROARRAY; DOWN REGULATION; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE FUNCTION; GENE IDENTIFICATION; GENETIC TRANSCRIPTION; HEART PROTECTION; HUMAN; OFF PUMP CORONARY SURGERY; REPERFUSION INJURY; UPREGULATION; BIOLOGY; CORONARY BLOOD VESSEL; DRUG EFFECTS; GENE EXPRESSION REGULATION; METABOLISM; MOLECULAR GENETICS; PROCEDURES;

ANESTHETICS; ANESTHETICS, INHALATION; ANESTHETICS, INTRAVENOUS; COMPUTATIONAL BIOLOGY; CORONARY ARTERY BYPASS, OFF-PUMP; CORONARY VESSELS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMANS; METHYL ETHERS; MOLECULAR SEQUENCE ANNOTATION; PROPOFOL;

EID: 84916235070     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2014.2669     Document Type: Article

References (52)

1. Shekar PS: Cardiology patient page. On-pump and off-pump coronary artery bypass grafting. Circulation 113: e51-e52, 2006.
2. Ehsan A, Shekar P and Aranki S: In novative surgical strategies: Minimally invasive CABG and off-pump CABG. Curr Treat Options Cardiovasc Med 6: 43-51, 2004.
3. Palmerini T, Biondi-Zoccai G, Riva DD, et al: Risk of stroke with percutaneous coronary intervention compared with on-pump and off-pump coronary artery bypass graft surgery: Evidence from a comprehensive network meta-analysis. Am Heart J 165: 910-917, 2013.
4. Harskamp RE, Lopes RD, Baisden CE, De Winter RJ and Alexander JH: Saphenous vein graft failure after coronary artery bypass surgery: pathophysiology, management and future directions. Ann Surg 257: 824-833, 2013.
5. Bakaeen FG, Chu D, Kelly RF, et al: Performing Coronary Artery Bypass Grafting Off-Pump May Compromise Long-Term Survival in a Veteran Population. Ann Thorac Surg 95: 1952-1958, 2013.
6. Moller CH, Penninga L, Wetterslev J, Steinbruchel DA and Gluud C: Off-pump versus on-pump coronary artery bypass grafting for ischaemic heart disease. Cochrane Database Syst Rev 3: CD007224, 2012.
7. Nathoe HM, Van Dijk D, Jansen EW, et al: A comparison of on-pump and off-pump coronary bypass surgery in low-risk patients. N Engl J Med 348: 394-402, 2003.
8. Orhan G, Sargin M, Senay S, et al: Systemic and myocardial infammation in traditional and off-pump cardiac surgery. Tex Heart Inst J 34: 160-165, 2007.
9. Selvanayagam JB, Petersen SE, Francis JM, et al: Effects of off-pump versus on-pump coronary surgery on reversible and irreversible myocardial injury: a randomized trial using cardiovascular magnetic resonanceimaging and biochemical markers. Circulation 109: 345-350, 2004.
10. Menasché P: The systemic factor: the comparative roles of cardiopulmonary bypass and off-pump surgery in the genesis of patient injury during and following cardiac surgery. Ann Thorac Surg 72: S2260-S2265; discussion S2265-S2266, S2267-S2270, 2001.
11. Tomic V, Russwurm S, Moller E, et al: Transcriptomic and proteomic patterns of systemic infammation in on-pump and off-pump coronary artery bypass grafting. Circulation 112: 2912-2920, 2005.
12. Brown J, Hernandez F, Beaulieu P, Clough R and Whited C, et al: Off-pump coronary artery bypass does not infuence biomarkers of brain injury, but does exacerbate the systemic infammatory response. J Clin Cell Immunik S2, 001, 2011.
13. Frassdorf J, De Hert S and Schlack W: Anaesthesia and myocardial ischaemia/reperfusion injury. Br J Anaesth 103: 89-98, 2009.
14. 2+) loading in intact hearts. Anesthesiology 96: 125-133, 2002.
15. Preckel B, Schlack W, Comfère T, Obal D, Barthel H and Thämer V: Effects of enfurane, isofurane, sevofurane and desflurane on reperfusion injury after regional myocardial ischaemia in the rabbit heart in vivo. Br J Anaesth 81: 905-912, 1998.
16. Lin E and Symons JA: Volatile anaesthetic myocardial protection: a review of the current literature. HSR Proc Intensive Care Cardiovasc Anesth 2: 105-109, 2010.
17. Garcia C, Julier K, Bestmann L, et al: Preconditioning with sevo-furane decreases PECAM-1 expression and improves one-year cardiovascular outcome in coronary artery bypass graft surgery. Br J Anaesth 94: 159-165, 2005.
18. Kawamura T, Kadosaki M, Nara N, et al: Effects of sevo furane on cytokine balance in patients undergoing coronary artery bypass graft surgery. J Cardiothorac Vasc Anesth 20: 503-508, 2006.
19. Huang Z, Zhong X, Irwin MG, et al: Synergy of isofura neprecon-ditioning and propofol postconditioning reduces myocardial reperfusion injury in patients. Clin Sci (Lond) 121: 57-69, 2011.
20. Corcoran TB, Engel A, Sakamoto H, O'shea A, O'callaghan-Enright S and Shorten GD: The effects of propofol on neutrophil function, lipid peroxidation and inflammatory response during elective coronary artery bypass grafting in patients with impaired ventricular function. Br J Anaesth 97: 825-831, 2006.
21. Sun H Y, Xue FS, Xu YC, et al: Propofol improves cardiac functional recovery after ischemia-reperfusion by upregulating nitric oxide synthase activity in the isolated rat hearts. Chin Med J (Engl) 122: 3048-3054, 2009.
22. Wang HY, Wang GL, Yu YH and Wang Y: The role of phosphoinositide-3-kinase/Akt pathway in propofol-induced postconditioning against focal cerebral ischemia-reperfusion injury in rats. Brain Res 1297: 177-184, 2009.
23. Kottenberg E, Thielmann M, Bergmann L, et al: Protection by remote ischemic preconditioning during coronary artery bypass graft surgery with isofurane but not propofol-a clinical trial. Acta Anaesthesiol Scand 56: 30-38, 2012.
24. Zaugg M, Lucchinetti E, Spahn DR, Pasch T, Garcia C and Schaub MC: Differential effects of anesthetics on mitochondrial K(ATP) channel activity and cardiomyocyte protection. Anesthesiology 97: 15-23, 2002.
25. Müllenheim J, Ebel D, Frässdorf J, Preckel B, Thämer V and Schlack W: Isoflurane preconditions myocardium against infarction via release of free radicals. Anesthesiology 96: 934-940, 2002.
26. Heusch G, Boengler K and Schulz R: Cardioprotection: nitric oxide, protein kinases and mitochondria. Circulation 118: 1915-1919, 2008.
27. He W, Zhang FJ, Wang SP, Chen G, Chen CC and Yan M: Postconditioning of sevofurane and propofol is associated with mitochondrial permeability transition pore. J Zhejiang Univ Sci B 9: 100-108, 2008.
28. Lucchinetti E, Hofer C, Bestmann L, et al: Gene regulatory control of myocardial energy metabolism predicts postoperative cardiac function in patients undergoing off-pump coronary artery bypass graft surgery: inhalational versus intravenous anesthetics. Anesthesiology 106: 444-457, 2007.
29. Fujita A, Sato JR, Rodrigues Lde O, Ferreira CE and Sogayar MC: Evaluating different methods of microarray data normalization. BMC Bioinformatic 7: 469, 2006.
30. Smyth GK: Limma: linear models for microarray data. In: Bioinformatics and Computational Biology Solutions using R and Bioconductor. Gentleman R, Carey, V, Dudoit S, Irazarry R and Huber W (eds). Spr inger, New York, N Y, p p397-420, 2005.
31. Benjamini Y and Hochberg Y: Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc B 1: 289-300, 1995.
32. Huang Da W, Sherman BT and Lempicki RA: Systematic and integrative analysis of large gene lists using DAVID Bioinformatics Resources. Nature Protoc 4: 44-57, 2009.
33. Tatusov RL, Natale DA, Garkavtsev I V, et al: The COG database: new developments in phylogenetic classifcation of proteins from complete genomes. Nucleic Acids Res 29: 22-28, 2001.
34. Altschul SF, Gish W, Miller W, Myers EW and Lipman DJ: Basic local alignment search tool. J Mol Biol 215: 403-410, 1990.
35. Zhang B, Kirov S and Snoddy J: WebGestalt: an integrated system for exploring gene sets in various biological contexts. Nucleic Acids Res 33: W741-W748, 2005.
36. Shi G, Zhang L and Jiang T: MSOAR 2.0: Incorporating tandem duplications into ortholog assignment based on genome rearrangement. BMC Bioinformatics 11: 10, 2010.
37. Malik V, Kale SC, Chowdhury UK, Ramakrishnan L, Chauhan S and Kiran U: Myocardial injury in coronary artery bypass grafting: On-pump versus off-pump comparison by measuring heart-type fatty-acid-binding protein release. Tex Heart Inst J 33: 321-327, 2006.
38. Mathur S, Farhangkhgoee P and Karmazyn M: Cardioprotective effects of propofol and sevofurane in ischemic and reperfused rat hearts: role of K(ATP) channels and interaction with the sodium-hydrogen exchange inhibitor HOE 642 (cariporide). Anesthesiology 91: 1349-1360, 1999.
39. Nobori K, Ito H, Tamamori-Adachi M, et al: ATF3 inhibits doxorubicin-induced apoptosis in cardiac myocytes: a novel cardioprotective role of ATF3. J Mol Cell Cardiol 34: 1387-1397, 2002.
40. Seijffers R, Allchorne AJ and Woolf CJ: The transcription factor ATF-3 promotes neurite outgrowth. Mol Cell Neurosci 32: 143-154, 2006.
41. Francis JS, Dragunow M and During MJ: Over expression of ATF-3 protects rat hippocampal neurons from in vivo injection of kainic acid. Brain Res Mol Brain Res 124: 199-203, 2004.
42. Chu HM, Tan Y, Kobierski LA, Balsam LB and Comb MJ: Activating transcription factor-3 stimulates 3', 5'-cyclic adenosine monophosphate-dependent gene expression. Mol Endocrinol 8: 59-68, 1994.
43. Weitzman JB, Fiette L, Matsuo K and Yaniv M: JunD protects cells from p53-dependent senescence and apoptosis. Mol Cell 6: 1109-1119, 2000.
44. Bergman MR, Cheng S, Honbo N, Piacentini L, Karliner JS and Lovett DH: A functional activating protein 1 (AP-1) site regulates matrix metalloproteinase 2 (MMP-2) transcription by cardiac cells through interactions with JunB-Fra1 and JunB-FosB heterodimers. Biochem J 369: 485-496, 2003.
45. Alfonso-Jaume MA, Bergman MR, Mahimkar R, et al: Cardiac ischemia-reperfusion injury induces matrix metalloproteinase-2 expression through the AP-1 components FosB and JunB. Am J Physiol Heart Circ Physiol 291: H1838-H1846, 2006.
46. Kumar S, Boehm J and Lee JC: p38 MAP kinases: key signalling molecules as therapeutic targets for infammatory diseases. Nat Rev Drug Discov 2: 717-726, 2003.
47. Muslin AJ: MAPK signalling in cardiovascular health and disease: molecular mechanisms and therapeutic targets. Clin Sci (Lond) 115: 203-218, 2008.
48. Wang Y, Huang S, Sah VP, et al: Cardiac muscle cell hypertrophy and apoptosis induced by distinct members of the p38 mitogen-activated protein kinase family. J Biol Chem 273: 2161-2168, 1998.
49. Boonyasrisawat W, Eberle D, Bacci S, et al: Tag polymorphisms at the A20 (TNFAIP3) locus are associated with lower gene expression and increased risk of coronary artery disease in type 2 diabetes. Diabetes 56: 499-505, 2007.
50. Xue H, Wang SX, Wang XJ, et al: Variants of tumor necrosis factor-induced protein 3 gene are associated with left ventricular hypertrophy in hypertensive patients. Chin Med J (Engl) 124: 1498-1503, 2011.
51. De Keulenaer GW, Wang Y, Feng Y, et al: Identifcation of IEX-1 as a biomechanically controlled nuclear factor-kappaB target gene that inhibits cardiomyocyte hypertrophy. Circ Res 90: 690-696, 2002.
52. Hirotani S, Otsu K, Nishida K, et al: Involvement of nuclear factor-kappaB and apoptosis signal-regulating kinase 1 in G-protein-coupled receptor agonist-induced cardiomyocyte hypertrophy. Circulation 105: 509-515, 2002.